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Biased alternative polyadenylation in human tissues <p>Bioinformatic analyses of the occurrence and mechanism of alternative polyadenylation in different human tissues reveals systematic  differences among tissues and suggests the involvement of both <it>trans</it>- and <it>cis</it>-regulatory elements.</p>
Abstract
Background: Alternative polyadenylation is one of the mechanisms in human cells that give rise
to a variety of transcripts from a single gene. More than half of the human genes have multiple
polyadenylation sites (poly(A) sites), leading to variable mRNA and protein products. Previous
studies of individual genes have indicated that alternative polyadenylation could occur in a tissue-
specific manner.
Results: We set out to systematically investigate the occurrence and mechanism of alternative
polyadenylation in different human tissues using bioinformatic approaches. Using expressed
sequence tag (EST) data, we investigated 42 distinct tissue types. We found that several tissues tend
to use poly(A) sites that are biased toward certain locations of a gene, such as sites located in
introns or internal exons, and various sites in the exon located closest to the 3' end. We also
identified several tissues, including eye, retina and placenta, that tend to use poly(A) sites not
frequently used in other tissues. By exploring microarray expression data, we analyzed over 20
genes whose protein products are involved in the process or regulation of mRNA polyadenylation.
Several brain tissues showed high concordance of gene expression of these genes with each other,
but low concordance with other tissue types. By comparing genomic regions surrounding poly(A)
sites preferentially used in brain tissues with those in other tissues, we identified several cis-
regulatory elements that were significantly associated with brain-specific poly(A) sites.
Conclusion: Our results indicate that there are systematic differences in poly(A) site usage among
human tissues, and both trans-acting factors and cis-regulatory elements may be involved in
regulating alternative polyadenylation in different tissues.
Background
Polyadenylation is essential for the 3'-end formation of most
mRNAs in eukaryotes. It involves two tightly coupled steps,
cleavage of a nascent mRNA and polymerization of a poly(A)
tail at the 3' end of the cleaved RNA. An array of factors are
involved in the process, including factors that seem to be
exclusively involved in polyadenylation, such as cleavage-
polyadenylation specificity factor (CPSF), cleavage stimula-
tory factor (CstF), cleavage factors (CFs) I and II, and poly(A)
polymerase (PAP), and factors that are involved in both poly-
adenylation and other cellular processes, including transcrip-
tion and mRNA splicing, such as RNA polymerase II,
Symplekin [1,2], PC4 [3], Ssu72 [4], heterogeneous nuclear
ribonucleoprotein (hnRNP) F [5], hnRNP H/H' [6], U2AF65
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[7], U1A [8-10], polypyrimidine tract binding protein (PTB)
[11], and SRp20 [12]. The fact that some factors are involved
in both polyadenylation and transcription and mRNA splic-
ing supports the notion that these processes are tightly cou-
pled [13,14]. In addition, the processing efficiency of
polyadenylation has a direct impact on the amount of mRNAs
produced [15]. Abnormal processing efficiency can lead to
human diseases such as thrombophilia [16].
Both biochemical and bioinformatic methods have been
applied to the identification of cis-regulatory elements (or cis
elements) for polyadenylation. The polyadenylation signal
(PAS) is located 10 to 35 nucleotides (nt) upstream of the
cleavage site, and serves as the binding site for CPSF. It is usu-
ally AAUAAA or a single nucleotide variant [17,18]. U/GU-
rich elements are located within approximately 40 nt down-
stream of the cleavage site [19,20], serving as the binding site
for CstF. In addition, several auxiliary upstream elements and
downstream elements have been found in viral or cellular
genes that can promote or repress polyadenylation [21-24].
Recent studies have shown that over half of the human genes
have multiple polyadenylation sites (poly(A) sites) [18,25].
Like alternative initiation and alternative splicing, alternative
polyadenylation (Alt-PA) contributes to the complexity of the
transcriptome in human cells by producing mRNAs with dif-
ferent 3' untranslated regions (3'UTRs) and/or encoding var-
iable protein isoforms [15]. The regulation of 3'UTRs by Alt-
PA can have a different impact on the mRNA metabolism, as
3'UTRs can contain various regulatory elements, such as AU-
rich elements responsible for mRNA stability [26,27] and
miRNA target sequences involved in the regulation of mRNA
translation [28-30]. The effect of Alt-PA on protein coding is
usually coupled with alternative splicing [15], and has been
demonstrated for several genes. Well-studied examples
include regulation of the IgM heavy chain gene [31] and reg-
ulation of calcitonin/calcitonin gene-related peptide [32,33].
Many poly(A) sites are preferentially used in certain tissues
and under specific cellular conditions [15,34]. It is not known,
however, whether the pattern of poly(A) site usage is system-
atically different among human tissues, which could result in
coordinate regulation of 3'UTRs or encoded proteins for a
large number of genes.
Here we describe our effort to study tissue-specific Alt-PA
events using bioinformatic approaches. Using expressed
sequence tag (EST) data and a newly developed method
named GAUGE (for global study of poly(A) site usage by
gene-based EST vote), we investigated 42 tissue types. We
found that several tissues tend to use poly(A) sites that are
biased toward certain locations of a gene, that is, 5' or 3'
poly(A) sites. For poly(A) sites located in the 3'-most exon,
biased usage was found in the nervous system, brain, pancre-
atic islet, ear, bone marrow, uterus, retina, placenta, ovary,
and blood. For poly(A) sites located in introns or internal
exons, biased usage was observed in cerebrum, soft tissue,
pancreas, lung, prostate, skin, placenta, esophagus, eye, ret-
ina, and blood. In addition, we found that eye, retina, and pla-
centa tend to use poly(A) sites not preferred in other tissues.
Using microarray expression data of polyadenylation-related
protein factors, we found that several brain tissues have high
concordance with each other, and low concordance with other
tissues. Finally, we identified several cis elements that are
preferentially associated with brain-specific poly(A) sites.
Taken together, our data suggest that systematic bias of Alt-
PA occurs in several human tissues, and both cis elements
and trans-acting factors are responsible for regulating Alt-
PA.
Results
Positional preference of polyadenylation in human 
tissues
We have previously shown that approximately 54% of human
genes have multiple poly(A) sites [18]. Poly(A) sites can be
located in various regions of a gene, including introns, inter-
nal exons, and 3'-most exons [18,25]. To address whether
there are positional preferences of Alt-PA in human tissues,
we evaluated tissue-specific poly(A) site usage based on the
relative position of a poly(A) site in a gene. We have previ-
ously classified human genes into three types according to the
locations of their poly(A) sites [18] (also shown in Figure 1 in
Additional data file 1). Briefly, genes with only one poly(A)
site are classified as type I genes, genes with multiple poly(A)
sites all in the 3'-most exon as type II genes, and genes with
poly(A) sites located in introns or internal exons as type III
genes. Alt-PA of type II genes may result in mRNAs with var-
iable 3'-UTRs, and the usage of poly(A) sites located in
introns or internal exons of type III genes can potentially have
an impact on protein sequence or lead to mRNAs with no in-
frame stop codons. Thus, by investigating the poly(A) site
usage of type II and III genes, one can address the question of
whether Alt-PA leads to variable 3'-UTRs or protein products
in certain tissue types. To this end, we classified poly(A) sites
of type II genes into 2F (the 5'-most poly(A) site), 2L (the 3'-
most poly(A) site), and 2M (middle poly(A) sites between 2F
and 2L); and classified poly(A) sites of type III genes into 3U
(poly(A) sites located upstream of the 3'-most exon) and 3D
(poly(A) sites located in the 3'-most exon) (Figure 1 in Addi-
tional data file 1).
Based on the EST tissue information obtained from the Uni-
Gene database [35] and assisted by the cDNA library classifi-
cation made by Yeo et al. [36], we first grouped cDNA
libraries into tissue types. In order to make quantitative com-
parisons, we used only non-normalized cDNA libraries. In
total, we grouped 609 non-normalized cDNA libraries into 42
tissue types, corresponding to 86,495 poly(A/T)-tailed ESTs
(Table 1 in Additional data file 1). To examine tissue-specific
usage of the three types of poly(A) sites in type II genes (2F,
2M, and 2L) and the two types of poly(A) sites in type III
genes (3U and 3D), we developed a method named GAUGE ashttp://genomebiology.com/2005/6/12/R100 Genome Biology 2005,     Volume 6, Issue 12, Article R100       Zhang et al. R100.3
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Genome Biology 2005, 6:R100
follows. Type II or type III genes cast votes for the usage of
different poly(A) site types in every tissue. The votes were
based on the number of supporting ESTs for certain poly(A)
sites, for example, 2F, 2M, or 2L. To account for the difference
of expression levels among genes, the number of ESTs for
each poly(A) site type was divided by the total number of
ESTs supporting each gene. Thus, for each gene, the sum of
the vote for all site types equals 1. The percentage of usage of
a poly(A) site type in a tissue can then be measured by the
votes cast by all genes expressed in that tissue divided by the
number of genes. We then carried out Chi-squared tests to
measure the bias of usage of different types of sites in each tis-
sue. For each poly(A) site type in a tissue, its percent of usage
was compared with the median percent of usage of all tissues.
The difference was normalized to the median and called dis-
tance (Figure 1). Complete lists of values for all tissues are
provided in Tables 2 and 3 in Additional data file 1.
Several tissues were found to have significantly biased (p
value < 0.05) usage of certain poly(A) sites of type II and/or
type III genes (Figure 1). Increased usage of 5'-most poly(A)
sites (2F) was observed for placenta, retina, blood, and ovary.
These tissues were also found to have decreased usage of 3'-
most poly(A) sites (2L), suggesting a shift of usage from 3'
poly(A) sites to 5' poly(A) sites. In bone marrow, uterus, ear,
brain, the nervous system, and pancreatic islet, however, the
preference is the opposite, with a decreased usage of 5'-most
poly(A) sites (2F) and increased usage of the 3' poly(A) sites
(2M and 2L), suggesting a shift of usage from 5' poly(A) sites
to 3' poly(A) sites. Similarly, placenta, eye, prostate, skin,
esophagus, retina, blood, and lung were found to have signif-
icantly increased usage of poly(A) sites located upstream of
the 3'-most exon (3U), whereas cerebrum, soft tissue, and
pancreas were found to have the opposite, biased to 3D, pref-
erence in poly(A) site usage. Interestingly, placenta, retina,
and blood were found to have positional preference of poly(A)
sites for both type II and type III genes, and the preferences
were both toward the 5' poly(A) sites (2F and 3U).
Tissues with distinct poly(A) site usage
We further asked the question whether some tissues tend to
use poly(A) sites that are not frequently used in other tissues.
The overall usage of a poly(A) site could be considered as its
'strength' [37]. Accordingly, frequently used poly(A) sites
were called 'strong' sites, whereas less frequently used sites
were called 'weak' sites. Presumably, strong sites are associ-
ated with favorable cis  elements for polyadenylation, and
weak sites either lack these elements or are associated with
repressing elements. Our goal was to identify tissues that had
significantly biased usage of strong or weak poly(A) sites. To
Tissue-specific positional preference of poly(A) site usage Figure 1
Tissue-specific positional preference of poly(A) site usage. (a) Tissue-
specific positional preference of type II genes. (b) Tissue-specific positional 
preference of type III genes. Distance to the median was calculated as 
(observed usage - median usage)/median usage. Only tissues with 
significant p values (<0.05, Chi-squared test) are shown here. 2F, 2M, and 
2L are the poly(A) sites closest to the 5' end, middle, and closest to the 3' 
end in a type II gene, respectively. 3U and 3D are poly(A) sites located 
upstream of the exon closest to the 3' end and poly(A) sites in the exon 
closest to the 3' end in a type III gene, respectively.
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Tissue-specific strong and weak poly(A) site usage Figure 2
Tissue-specific strong and weak poly(A) site usage. For each tissue, three 
bars represent the distance to the median usage according to three 
different cutoffs for the classification of strong and weak sites, for 
example, 60%, 75% and 90%. For each gene at a given cutoff, the poly(A) 
site with the percent of supporting ESTs above the cutoff was classified as 
a strong site. If there was a strong poly(A) site, other sites of the same 
gene were classified as weak sites. Only values for the weak sites are 
shown. Significant ones (p value < 0.05, Chi-squared test) are marked with 
asterisks.
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Table 1
Polyadenylation-related protein factors
Gene name Gene ID* U95Av2 probe-sets U133A probe-sets
1 CPSF-160, cleavage and polyadenylation specificity factor 1, 160 kDa 29894 33132_at 201638_s_at
201639_s_at
33132_at
2 CPSF-100, cleavage and polyadenylation specificity factor 2, 100 kDa 53981 NA NA
3 CPSF-73, cleavage and polyadenylation specificity factor 3, 73 kDa 51692 NA NA
4 CPSF-30, cleavage and polyadenylation specificity factor 4, 30 kDa 10898 35743_at 206688_s_at
5 CFI25, cleavage factor Im, 25 kDa 11051 39142_at 202697_at
213461_at
6 CFI68, cleavage factor Im, 68 kDa 11052 35757_at 202469_s_at
202470_s_at
7h F i p 1 ,   Saccharomyces cerevisiae Fip1p like 81608 NA 221007_s_at
8 CstF50, cleavage stimulatory factor subunit 1, 50 kDa 1477 32723_at 202190_at
32723_at
9 CstF-64, cleavage stimulatory factor subunit 2, 64 kDa 1478 40334_at 204459_at
10 CstF-77, cleavage stimulatory factor subunit 3, 77 kDa 1479 41183_at 203947_at
11 τ CstF-64, cleavage stimulatory factor subunit 2, 64 kDa, tau variant 23283 41248_at 212901_s_at
212905_at
12 CFIIA, HEAB, ATP/GTP binding protein, component of CFIIAm [52] 10978 33149_at 204370_at
13 PCF11, pre-mRNA cleavage complex II protein [53] 51585 41665_at 203378_at
14 PABPII, poly(A) binding protein, nuclear 1 8106 39050_at 201544_x_at
201545_s_at
213046_at
15 Symplekin [1,2] 8189 32402_s_at 32402_s_at
202339_at
16 HNRPF, heterogeneous nuclear ribonucleoprotein F [5] 3185 38071_at 201376_s_at
17 HNRPH, heterogeneous nuclear ribonucleoprotein H1 (H) [6] 3187 41292_at 201031_s_at
213470_s_at
213472_at
18 HNRPH', heterogeneous nuclear ribonucleoprotein H2 (H') [6] 3188 41131_f_at
41132_r_at
201132_at
19 U2AF65, U2 small nuclear RNA auxiliary factor2 [7] 11338 32556_at 218381_s_at
218382_s_at
20 U1A, U1 small nuclear ribonucleoprotein polypeptide A [8,10] 6626 40842_at 201770_at
21 PC4, transcriptional coactivator [3] 10923 36171_at 212857_x_at
214512_s_at
221727_at
22 Similar to HSPC182 protein, human HomoloGene of yeast Ssu72 [4] 286528 NA NA
23 SRp20 [12] 6428 351_f_at
40457_at
202899_s_at
208672_s_at
208673_s_at
24 PTB, polypyrimidine tract binding protein, also known as hnRNP I [11] 5725 40593_at 202189_x_at
211270_x_at
211271_x_at
212015_x_at
212016_s_at
216306_x_at
25 nPTB, polypyrimidine tract binding protein 2 58155 NA 218683_at
26 PAP, poly(A) polymerase 10914 34855_at 209388_at
212718_at
212720_at
215374_at
222035_s_at
References supporting the role of a given factor in mRNA polyadenylation can be found in review articles Proudfoot et al. [54], Zhao et al. [21], and 
Edwalds-Gilbert et al. [15], if not otherwise noted. Some genes do not have corresponding probe sets on a microarray, as indicated by NA. *Gene 
IDs are NCBI Entrez Gene IDs [55].http://genomebiology.com/2005/6/12/R100 Genome Biology 2005,     Volume 6, Issue 12, Article R100       Zhang et al. R100.5
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this end, we classified 22,865 poly(A) sites from 7,524 alter-
natively polyadenylated human genes in our polyA_DB data-
base [38] into strong and weak sites by their supporting ESTs
from non-normalized cDNA libraries. In order to have robust
results, we used three cutoffs for the classification, 60%, 75%,
and 90%. For each gene at a given cutoff, the poly(A) site with
the percent of supporting ESTs above the cutoff was classified
as a strong site. If there was a strong poly(A) site, other sites
of the same gene were classified as weak sites. It is noteworthy
that we used ESTs derived from a large number of cDNA
libraries, corresponding to 42 tissue types (Table 1 in Addi-
tional data file 1). Thus, the classification should not be biased
by ESTs from certain tissue types, and the strength should
reflect poly(A) site usage in most tissues, that is, strong sites
are 'globally preferred', whereas weak sites are not.
To examine the usage of strong and weak poly(A) sites, we
applied the GAUGE method described above with the modifi-
cation that genes voted for strong and weak sites. Among 42
tissues investigated, retina, eye, placenta, uterus, and testis
had significant biases (p value < 0.05) using at least one of the
cutoffs (Figure 2; complete lists of values for all tissues using
different cutoffs are provided in Tables 4-6 in Additional data
file 1). All the significant biases were toward the weak sites.
Among these, retina, eye, and placenta had consistent biases
at all cutoffs. Interestingly, retina and placenta were found to
be biased to 2F poly(A) sites and eye, retina, and placenta
were found to be biased to 3U poly(A) sites (see above), indi-
cating that eye, retina, and placenta use distinct sets of
poly(A) sites that are of the types 2F and 3U. As testis was
found to be biased to weak sites only using the 90% cutoff, it
appears that a set of genes expressed in the testis select
poly(A) sites that are strongly preferred, if not uniquely used,
in testis. Taken together, our observations of positional bias
and distinct poly(A) site usage suggest that there is biased
usage of poly(A) sites in certain human tissues. As these tis-
sue-specific preferences were observed on a global rather
than gene-specific level, the mechanism for these biases may
lie in tissue-specific regulation of expression of certain polya-
denylation factors.
Differential expression of polyadenylation-related 
protein factors among tissues
We then wished to address whether there were differences in
gene expression of trans-acting factors among different tis-
sues, which might be responsible for the observed tissue-spe-
cific poly(A) site usage. To this end, we obtained mRNA
expression data from two microarray studies [39,40], involv-
ing U95Av2 and U133A Affymetrix GeneChips (Affymetrix,
Santa Clara, CA, USA), respectively. To cross-validate the
data, we focused on 25 tissue types whose gene expression
was analyzed in both studies. From the literature we identi-
fied 26 factors that were known or had been suggested to play
roles in nuclear polyadenylation (Table 1). Of these 26 factors,
21 had probes on both U95Av2 and U133A microarrays. In
addition, U133A had probes for two additional genes, and
three factors had no probes on either microarray.
Microarray data were first normalized to the 75 percentile
within each tissue, and were then subjected to hierarchical
cluster analysis based on the Pearson correlations of expres-
sion levels of polyadenylation factors. As shown in Figure 3,
there are conspicuous differences among different tissues.
Interestingly, several brain tissues, including amygdala, tha-
lamus, fetal brain, whole brain, and caudate nucleus, form a
distinct cluster in both datasets (Figure 3a,b). To assess the
robustness of cluster analysis, we compared the results of the
U95Av2 and U133A studies. We calculated the Pearson corre-
lation coefficients (r) between all pairs of 25 tissues using the
expression of the 21 polyadenylation factors. The r  values
ranged from -1 to 1, with values close to 1 indicating high con-
cordance, and values close to -1 indicating low concordance.
We then clustered tissues based on r values obtained from
both U95Av2 and U133A datasets, and presented the values
in a heatmap (Figure 3c). We found that the expression values
of the 21 polyadenylation factors were well correlated (r >
0.75) for most tissues, suggesting consistency of these two
studies with respect to the factors investigated. As expected, a
distinct cluster containing several brain tissues (amygdala,
thalamus, caudate nucleus, fetal brain, and whole brain) can
be discerned (average r-value 0.87 within the cluster), which
showed low concordance with other tissues (average r-value
0.55 between the cluster and other tissues). The clustering
result to some extent agrees with our studies using ESTs. For
example, lung, ovary, placenta, and prostate, which were
among the 25 tissues in the microarray studies, had signifi-
cant positional bias towards 5' poly(A) sites (2F or 3U; Figure
1), and brain and cerebrum had a statistically significant posi-
tional preference for 3' poly(A) sites (2L or 3D; Figure 1). Con-
sistent with these observations, expression data from brain
tissues correlated poorly (mean r-value of 0.41) with those
from placenta, lung, ovary, or prostate (Figure 3c).
Gene expression of polyadenylation factors Figure 3 (see following page)
Gene expression of polyadenylation factors. (a) Two-way hierarchical clustering of the U95Av2 data using 21 polyadenylation factors. (b) Two-way 
hierarchical clustering of the U133A data using 23 polyadenylation factors. See Table 1 for polyadenylation factors in each dataset. Tissues and genes that 
are consistently clustered together in both datasets are marked by gray lines. (c) Correlation of mRNA expression levels of 21 polyadenylation-related 
factors across 25 human tissues (upper diagonal, data from U133A; lower diagonal, data from U95Av2). Based on the scale displayed on top of the figure, 
small squares are colored to represent the extent of correlation between mRNA expression levels of the 21 genes in each pair of human tissues. DRG, 
dorsal root ganglion.R100.6 Genome Biology 2005,     Volume 6, Issue 12, Article R100       Zhang et al. http://genomebiology.com/2005/6/12/R100
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Figure 3 (see legend on previous page)
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Two studies showed that, of the 21 genes, U1A and PTB had a
similar expression pattern across tissues, as did PC4, PCF11,
τ CstF-64, and hnRNP H'. The difference between brain tis-
sues and others was mainly attributable to the expression of
four genes: The expression of PTB and U1A was consistently
lower in brain tissues than in other tissues (p value < 0.05 by
t test; Figure 4a,b), whereas the relative expression levels of
PC4 and τ CstF-64 were consistently higher in brain tissues (p
value < 0.05 by t test; Figure 4c,d). Comparisons of expres-
sion levels between brain tissues and other tissues for the rest
of the 17 factors, however, did not show such differences in
either U95Av2 or U133A datasets (Figure 2 in Additional data
file 1). In addition, neural polypyrimidine tract binding pro-
tein (nPTB), whose expression value was only available in the
U133A study, was also found to be preferentially expressed in
brain tissues (Figure 4e), consistent with previous reports
that it was primarily expressed in neuronal cells.
Cis elements associated with poly(A) sites 
preferentially used in brain tissues
The well-established paradigm in gene regulation is that
trans-acting factors and cis elements work in concert. Our
observations of biased Alt-PA in certain human tissues
prompted us to investigate candidate cis  elements. We
focused on brain tissues in this study, as they were found to
have biased usage of poly(A) sites, and several brain tissues
had similar gene expression patterns for a number of polya-
denylation factors, which could make it straightforward to
correlate the expression of trans factors and the usage of
identified cis elements. To select cis elements that are prefer-
entially present near poly(A) sites used in brain tissues, we
first selected poly(A) sites belonging to genes that have mul-
tiple poly(A) sites and are expressed in brain tissues. We then
focused on the -100/+100 nt genomic region of poly(A) sites
(the poly(A) site is arbitrarily set at position 0) for identifica-
tion of cis elements. This is based on previous studies that
indicated the -100/+100 nt region had a different nucleotide
composition to regions further upstream (<-100) or down-
stream (>+100) of a poly(A) site [18,37]. We divided the
genomic sequence surrounding a poly(A) site into four
regions: -40/-1 nt, where the PAS is located; +1/+40 nt,
where U/GU-rich elements are usually located; -100/-41 nt,
where auxiliary upstream elements may be located; and +41/
+100 nt, where auxiliary downstream elements may be
located (Figure 5a). In addition, we used the -300/-200 and
+200/+300 regions as control regions, which, based on our
current knowledge of cis  elements for polyadenylation,
should contain very few, if any, regulatory elements for poly-
adenylation. To identify cis elements in brain-specific poly(A)
sites, we took an approach that is similar to the method
described in [24]. Briefly, hexamers (4,096 in total) were
assigned with two scores: zun, the difference between the fre-
quency of occurrence in a specific sequence region, for exam-
ple, -100/-41, of poly(A) sites used in brain tissues (a total of
2,495 sites) and those not used in the brain (a total of 3,297
sites); and zpc, the difference between the frequency of occur-
rence in a specific poly(A) region and the frequency of occur-
rence in control regions. We then selected hexamers with
both zun and zpc greater than 2.5. A z score of 2.5 corresponds
to a p value of approximately 0.01 in a normal distribution. To
avoid the identification of cis elements that are globally pre-
ferred, we filtered out hexamers with zsw > 2.5, where zsw is
the difference between the frequency of occurrence in a spe-
cific sequence region of strong poly(A) sites and that of weak
poly(A) sites, using 75% as the cutoff for classification of
strong and weak sites. Selected hexamers were grouped by
their mutual similarities, and groups with more than three
hexamers were used to build sequence logos. In addition,
position-specific scoring matrices (PSSMs) were derived
from the logos, and used to search corresponding cis ele-
ments in poly(A) regions.
We identified five putative elements that were significantly
over-represented in various regions of poly(A) sites
preferentially used in brain tissues (Figure 5). Among these, a
GU element (Figure 5d, right panel) was identified in region
+1/+40, which seems to be the binding site for CstF-64. GU
elements should be general enhancers for polyadenylation.
As we filtered out hexamers that are significantly associated
with strong poly(A) sites, the fact that a GU element still
remains indicates that the GU element is strongly biased to
poly(A) sites used in brain tissues. This notion is in line with
the difference between the percent of hits profile of the GU
element in brain specific poly(A) sites compared to non-brain
poly(A) sites (Figure 5d, right panel). As the expression of
CstF-64 is similar between brain tissues and other tissues and
the expression of τ CstF-64 is significantly higher in brain tis-
sues, the identified element could be the preferred binding
site of τ CstF-64. This prediction, however, needs to be vali-
dated in wet lab experiments. In addition, we found that the
UCUUU element (Figure 5d, left panel) was over-represented
in region +1/+40. UCUUU is known to be the binding site of
PTB [11,41]. Interestingly, the UUC/GUG element identified
in the -100/-41 region (Figure 5b, right panel) also resembles
PTB binding sites. As shown by the microarray data, PTB
expression is low in brain tissues, whereas the nPTB level is
high. Thus, it will be interesting to examine whether nPTB
binds to these cis elements and plays a role in poly(A) site
selection in brain tissues. Furthermore, two other elements
(Figure 5b, left panel and Figure 5c) seem to be related to U-
Boxplots of mRNA expression of several factors in brain and other tissues Figure 4 (see following page)
Boxplots of mRNA expression of several factors in brain and other tissues. (a) PTB, (b) U1A, (c) τ CstF-64, (d) PC4, and (e) nPTB. All factors except 
nPTB were present in both the U95Av2 and U133A datasets. Brain tissues include amygdala, thalamus, caudate nucleus, fetal brain, and whole brain. 
Expression values lower in brain tissues than other tissues are in green; and those higher in brain tissues are in red.R100.8 Genome Biology 2005,     Volume 6, Issue 12, Article R100       Zhang et al. http://genomebiology.com/2005/6/12/R100
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Figure 4 (see legend on previous page)
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rich elements and the AAUAAA PAS. Their significance is not
clear, despite the fact that their percent of hits profiles differ
between poly(A) sites preferred in brain tissues and those not
preferred (Figure 5b,c). They could well be general regulatory
elements that were not filtered out using zsw  scores (see
above). In line with this notion, both elements only had four
supporting hexamers, whereas the GU element and UCUU
element had five supporting hexamers, and the UUC/GUG
element had seven supporting hexamers (Figure 3 in Addi-
tional data file 1).
Discussion
We have detected biased poly(A) site usage in several human
tissues using GAUGE. GAUGE was designed to detect system-
atic bias of poly(A) site usage in different tissues. The idea is
that individual genes may not have statistical power for detec-
tion of overall trend, whereas significant patterns could
emerge using a large number of genes. Although the numbers
of cDNA libraries and ESTs for some tissue types were suffi-
cient to allow us to make statistical conclusions, some others
did not have enough numbers for sensitive detections, such as
heart and thymus (Table 1 in Additional data file 1). If more
ESTs become available, this approach could be carried out for
these tissues in the future. On a similar note, an inherent lim-
itation of our approach is that we could not assess the bias for
individual genes due to lack of statistical power, which, at the
current stage, is best addressed by wet lab experiments.
For poly(A) sites located in the 3'-most exon, the nervous sys-
tem, brain, pancreatic islet, ear, bone marrow, and uterus
tend to use 3' poly(A) sites, whereas retina, placenta, ovary,
and blood tend to use 5' poly(A) sites. This observation indi-
cates that genes may express mRNAs with longer 3'UTRs in
certain tissues than in others, and the pattern is systemati-
cally controlled. Consistent with our observation, it has been
suggested that brain tissues tend to express larger genes than
other tissues [42], presumably due to the low mitotic activity
of highly differentiated cells in the brain allowing more time
to express long transcripts. Our data also suggest that each
tissue type may have a defined 'program' to produce mRNAs
with certain length. Given that 3'UTRs contain various RNA
regulatory elements, it is conceivable that this mode of gene
regulation could coordinately influence mRNA metabolism
for a large number of genes. However, the exact impact of this
systematic control needs to be explored in wet lab settings. In
addition, lung, prostate, skin, placenta, esophagus, eye, ret-
ina, and blood were found to have higher usage of poly(A)
sites located upstream of the 3'-most exon than other tissues.
The usage of these poly(A) sites could result in truncated
mRNAs without in-frame stop codons, or mRNAs encoding
distinct protein isoforms. The coordinated regulation of
poly(A) site usage could, therefore, lead to a switch in the
expression of protein isoforms. As poly(A) sites located
upstream of the 3'-most exon are next to introns and internal
exons, regulation of this type of poly(A) sites is complicated
by other factors, such as transcription and mRNA splicing.
For example, both the IgM heavy chain gene [31] and the cal-
citonin/calcitonin gene-related peptide [32,33] gene switch
protein products by using different poly(A) sites under cer-
tain cellular conditions. In both cases, alternative splicing was
also shown to be involved.
We found that the expression of U1A, PC4, τ CstF-64, PTB,
and nPTB were significantly different between brain tissues
and other tissues. The differences may contribute to the dis-
tinct Alt-PA pattern in the brain. It has been shown that brain
tissues exhibit high levels of alternative splicing, especially
exon skippings [36], which is consistent with our observation
of a low expression level of PTB, a repressor of mRNA splicing
[43], in brain tissues. It has also been shown that PTB can
modulate polyadenylation efficiency by competing with CstF-
64 for binding to downstream U/GU-rich elements [11]. nPTB
shares high sequence homology with PTB [44,45] (Figure 4a
in Additional data file 1), but its activity in regulating polya-
denylation has not been studied. U1A can modulate polyade-
nylation by interacting with the poly(A) polymerase [10].
Furthermore, PC4 can regulate polyadenylation by interact-
ing with CstF-64 [3]. τ CstF-64 appears to be a paralog of
CstF-64 (75% identity in protein sequence), which has been
previously reported to be highly expressed in the brain and
testis [46]. CstF-64 and τ CstF-64 are highly homologous
(>95% identity; Figure 4b in Additional data file 1) in both the
amino-terminal RNA binding domain, which is responsible
for interacting with U/GU-rich elements, and the carboxy-
terminal 63 amino acid region, which has been implicated in
binding to PC4 [3], indicating that the functions of CstF-64
and  τ CstF-64 may overlap extensively. Thus, nPTB and
τ CstF-64 appear to be functional homologs of PTB and CstF-
64, respectively. Our observations that both nPTB and τ CstF-
64 mRNA levels are higher in brain tissues than other tissues,
whereas the PTB mRNA level is lower in brain tissues and
there is no difference in CstF-64 mRNA expression between
brain tissues and other tissues (Figure 2 in Additional data
file 1), indicate that brain tissues use a different set of genes to
regulate splicing and polyadenylation, albeit their functions
Brain-specific over-represented cis elements Figure 5 (see following page)
Brain-specific over-represented cis elements. (a) Schematic of the four poly(A) regions investigated. (b) Identified cis elements in -100/-41. (c) Identified cis 
elements in -40/-1. (d) Identified cis elements in +1/+40. Logos are shown for cis elements. Under each logo is the percent of hits for the corresponding cis 
element in poly(A) sites preferred in brain tissues (red), poly(A) sites not preferred in brain tissues (green), and all poly(A) sites (black). In the graphs, the 
y-axis is the percent of hits, and the x-axis is the distance to the poly(A) site. Horizontal dotted lines are the average value, and vertical dotted lines are the 
-100, -40, +40, +100 nt positions.R100.10 Genome Biology 2005,     Volume 6, Issue 12, Article R100       Zhang et al. http://genomebiology.com/2005/6/12/R100
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Figure 5 (see legend on previous page)
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may be similar to their counterparts in other tissues.
In this study, we used brain tissues as a model to correlate the
presence of cis elements and expression of trans factors. The
reason to choose brain tissues is that biased usage of poly(A)
sites was observed in brain tissues and high concordance of
gene expression of polyadenylation factors was detected
among several brain tissues. The latter is important as micro-
array data often contain noise. Using two datasets and several
brain tissues gave us assurance as to the quality of the data.
On the other hand, we only focused on known polyadenyla-
tion factors. Other protein factors that may also be involved in
the regulation of polyadenylation were not examined in this
study. Nevertheless, the significant presence of PTB and
CstF-64 binding sites near poly(A) sites preferentially used in
brain tissues correlates with high expression levels of nPTB
and  τ CstF-64, which suggests a model where nPTB and
τ CstF-64 function cooperatively in poly(A) site selection in
brain tissues. However, the exact details of the interactions
need to be investigated in the future. In addition, the role of
PC4 in regulating poly(A) site selection in the brain is to be
examined, as a higher level of PC4 was observed in brain tis-
sues versus other tissues. Furthermore, the same approach
for identifying tissue-specific usage of cis elements can be
applied to other tissue types. Ear, retina, and placenta will be
particularly interesting to study, as they were found to use
poly(A) sites that are not frequently used in other tissues and
all three tissues tend to use 5' poly(A) sites.
Materials and methods
Datasets and resources
Genes with alternative poly(A) sites, their annotations includ-
ing poly(A) positions and supporting EST evidence were
obtained from polyA_DB [38]. General annotations of cDNA
libraries were downloaded from the UniGene database [35]. A
PERL script was used to determine whether a cDNA library is
normalized or non-normalized. A cDNA library is classified as
non-normalized if its annotation contains 'non-normaliz' or
'not normaliz', or does not contain the string 'normaliz' in any
part of the annotation. Assisted by tissue annotations for
cDNA libraries made by Yeo et al. [36], we grouped 609 non-
normalized cDNA libraries into 42 tissue types. Microarray
datasets [39,40] were downloaded from NCBI GEO [47].
Mappings of probe-sets to LocusLink IDs were obtained from
the Affymetrix website [48].
Identification of biased usage of poly(A) sites in human 
tissues by GAUGE
For genes with more than one poly(A) site, we used the
number of supporting ESTs to classify strong or weak sites.
To make robust assessment, we used three cutoffs for the
classification, specifically, 60%, 75%, and 90%. For each cut-
off, the poly(A) site with the percent of supporting ESTs above
the cutoff was classified as a strong site. If there was a strong
poly(A) site, other sites of the same gene were classified as
weak sites. In addition, we required that the sum of ESTs for
all weak sites must be above 1. Type II and type III genes were
classified as previously described [18]. Poly(A) sites in type II
genes were classified into 2F (the 5'-most poly(A) site), 2L
(the 3'-most poly(A) site), and 2M (middle poly(A) sites
between 2F and 2L); and poly(A) sites in type III genes were
classified into 3U (poly(A) sites located upstream of the 3'-
most exon) and 3D (poly(A) sites located in the 3'-most exon).
To study the usage of poly(A) sites, we allowed each gene to
cast votes for the usage of poly(A) site types according to sup-
porting ESTs. The vote was calculated as follows:
where   is the votes for the usage of poly(A) site type p
(strong/weak; or 2F/2M/2L; or 3U/3D) in tissue type t; 
is the number of poly(A/T)-tailed ESTs supporting the usage
of poly(A) site type p for gene g in tissue t; and Eg,t is the total
number of poly(A/T)-tailed ESTs associated with gene g in
tissue t. Percent of usage of a poly(A) type in a tissue (also
called observed usage) was calculated by dividing the votes by
the total number of genes investigated in the tissue. The
median usage for a poly(A) site type is the median of the per-
cent of usage values for the type of all tissues. The distance to
the median usage was calculated by (observed usage - median
usage)/median usage. A Chi-squared test was performed for
each tissue with the null hypothesis that the usage of a given
poly(A) site type in the tissue is not different from the median
usage. The analyses were carried out in R [49].
Microarray data analysis of trans-acting factors
mRNA expression data were obtained from the NCBI GEO
database [47]. The average difference values were normalized
to the 75th percentile within each chip. When more than one
probe-set mapped to the same gene, the median value was
used to represent the mRNA expression level. For tissue types
with more than one sample, median values were used. Clus-
tering of tissues and genes with respect to expression profiles
of polyadenylation factors were carried out using the Cluster
program [50], and presented using TreeView [50].
Identification of candidate cis elements
Genomic regions -100/+100 nt surrounding the poly(A) sites
were divided into four sub-regions: -100/-41 nt, -40/-1 nt, +1/
+40 nt, and +41/+100 nt. Frequencies of occurrence of all
4,096 hexamers were calculated in each sub-region and in
control regions (-300/-200 and +200/+300). Three scores
were used to select hexamers in each sub-region: zun, the dif-
ference between the frequency of occurrence from poly(A)
sites used in the brain and those from poly(A) sites not used
in the brain; zpc, the difference between the frequency of
occurrence in the sub-region and the frequency of occurrence
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in the control regions; and zsw, the difference between the fre-
quency of occurrence in the sub-region of strong poly(A) sites
and weak poly(A) sites using the 75% cutoff (see above). All z
scores were calculated using the following equations. For hex-
amers in set a and set b, zab was calculated as follows:
where
and Na and Nb are the total number of hexamers associated
with set a and set b, respectively. fa(H) and fb(H) are the
frequency of occurrence of hexamer H in set a and set b,
respectively. A cutoff of 2.5 was used to select hexamers that
are significantly biased to one set, which corresponded to a p
value of approximately 0.01 in a normal distribution. Thus,
selection of hexamers by two criteria should result in less than
one falsely identified hexamer (4,096 × 0.01 × 0.01 = 0.4).
Hexamers that have both zun and zpc above the cutoff, and zsw
below the cutoff, were selected for further analysis.
Selected hexamers were grouped based on their mutual dis-
tances using the hierarchical clustering function in program
R with the average agglomerative method. The distance
between two hexamers is their dissimilarity score (d) calcu-
lated as follows: d = 6 - s, where s is a similarity score. s was
calculated using a dynamic programming method for global
sequence alignment that does not allow gaps, and match and
mismatch scores were 1 and 0, respectively. A cutoff of 2.5
was used to group hexamers. Only groups containing more
than three hexamers after clustering were selected for further
analysis. Hexamers in the same group were aligned using a
multiple sequence alignment method using the hexamer with
the highest frequency of occurrence as the seed. All other hex-
amers were aligned to the seed. Aligned hexamers were used
to build sequence logos to represent cis elements using the
W e b  L o g o  t o o l  [ 5 1 ] .  T h e  h e i g h t  o f  e a c h  n u c l e o t i d e  i n  a
sequence logo reflects the occurrence of the nucleotide in the
cis element. Aligned hexamers were also used to generate
PSSM, which were used to search sequences containing
poly(A) sites. For each position in a given cis element, the
score was calculated by:
S(n,p) = log2(f(n,p)/f(n))
where S(n,p) is the score for nucleotide n at position p, f(n,p)
is the frequency of occurrence of nucleotide n at position p,
and f(n) is the frequency of occurrence of nucleotide n in a
specific poly(A) region. Sequences with positive scores com-
pared with PSSM were called hits.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a PDF contain-
ing supplemental tables and figures.
Additional data file 1 A PDF containing supplemental tables and figures A PDF containing supplemental tables and figures. The tables list:  Table 1, tissues, cDNA libraries, genes, ESTs, and poly(A) sites used  in this study; Table 2, poly(A) site usage of type II genes; Table 3,  poly(A) site usage of type III genes; Table 4, usage of strong and  weak poly(A) sites using 60% as cutoff; Table 5, usage of strong and  weak poly(A) sites using 75% as cutoff; Table 6, usage of strong and  weak poly(A) sites using 90% as cutoff. The figures show: Figure 1,  Schematic representation of three types of genes; Figure 2, Box- plots of mRNA expression levels of polyadenylation-related factors  in brain tissues versus other tissues; Figure 3, selection of hexam- ers in different poly(A) regions; Figure 4, multiple sequence align- ments of PTB and nPTB and CstF-64 and τ CstF-64. Click here for file
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